| [1] |
Sung H, Ferlay J, Siegel RL, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J ClinCA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660 |
| [2] |
Culp MB, Soerjomataram I, Efstathiou JA, et al.
Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur UrolEur Urol, 2020, 77(1): 38-52.
doi: 10.1016/j.eururo.2019.08.005 |
| [3] |
Ristau BT, O'Keefe DS, Bacich DJ.
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research[J]. Urol OncolUrol Oncol, 2014, 32(3): 272-279.
doi: 10.1016/j.urolonc.2013.09.003 |
| [4] |
Chang SS, O'Keefe DS, Bacich DJ, et al.
Prostate-specific membrane antigen is produced in tumor-associated neovasculature[J]. Clin Cancer ResClin Cancer Res, 1999, 5(10): 2674-2681.
|
| [5] |
Marchal C, Redondo M, Padilla M, et al.
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol HistopatholHistol Histopathol, 2004, 19(3): 715-718.
doi: 10.14670/HH-19.715 |
| [6] |
O'Keefe DS, Bacich DJ, Huang SS, et al.
A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies[J]. J Nucl MedJ Nucl Med, 2018, 59(7): 1007-1013.
doi: 10.2967/jnumed.117.203877 |
| [7] |
Eiber M, Weirich G, Holzapfel K, et al.
Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer[J]. Eur UrolEur Urol, 2016, 70(5): 829-836.
doi: 10.1016/j.eururo.2015.12.053 |
| [8] |
Chen MX, Zhang Q, Zhang CW, et al.
Combination of 68Ga-PSMA PET/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis[J]. J Nucl MedJ Nucl Med, 2019, 60(7): 944-949.
doi: 10.2967/jnumed.118.221010 |
| [9] |
Donato P, Roberts MJ, Morton A, et al.
Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(1): 20-30.
doi: 10.1007/s00259-018-4160-7 |
| [10] |
Richenberg J, Løgager V, Panebianco V, et al.
The primacy of multiparametric MRI in men with suspected prostate cancer[J]. Eur RadiolEur Radiol, 2019, 29(12): 6940-6952.
doi: 10.1007/s00330-019-06166-z |
| [11] |
Donato P, Morton A, Yaxley J, et al.
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: is 68Ga-PSMA PET/CT guided biopsy the future?[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(8): 1843-1851.
doi: 10.1007/s00259-019-04620-0 |
| [12] |
Kalapara AA, Nzenza T, Pan HYC, et al.
Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology[J]. BJU IntBJU Int, 2020, 126(1): 83-90.
doi: 10.1111/bju.14858 |
| [13] |
Evangelista L, Zattoni F, Cassarino G, et al.
PET/MRI in prostate cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(3): 859-873.
doi: 10.1007/s00259-020-05025-0 |
| [14] |
Liu FY, Sheng TW, Tseng JR, et al.
Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET-CT vs. PET-MRI[J]. Br J RadiolBr J Radiol, 2022, 95(1131): 20210728-.
doi: 10.1259/bjr.20210728 |
| [15] |
Herlemann A, Wenter V, Kretschmer A, et al.
68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer[J]. Eur UrolEur Urol, 2016, 70(4): 553-557.
doi: 10.1016/j.eururo.2015.12.051 |
| [16] |
Baas DJH, Schilham M, Hermsen R, et al.
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection[J]. Prostate Cancer Prostatic DisProstate Cancer Prostatic Dis, 2022, 25(1): 65-70.
doi: 10.1038/s41391-021-00452-y |
| [17] |
Franklin A, Yaxley WJ, Raveenthiran S, et al.
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer[J]. BJU IntBJU Int, 2021, 127(1): 71-79.
doi: 10.1111/bju.15134 |
| [18] |
Abufaraj M, Grubmüller B, Zeitlinger M, et al.
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT (MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(10): 2169-2177.
doi: 10.1007/s00259-019-04361-0 |
| [19] |
Kimura S, Abufaraj M, Janisch F, et al.
Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis[J]. Prostate Cancer Prostatic DisProstate Cancer Prostatic Dis, 2020, 23(1): 1-10.
doi: 10.1038/s41391-019-0156-z |
| [20] |
Hofman MS, Lawrentschuk N, Francis RJ, et al.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. LancetLancet, 2020, 395(10231): 1208-1216.
doi: 10.1016/S0140-6736(20)30314-7 |
| [21] |
Uprimny C, Svirydenka A, Fritz J, et al.
Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2018, 45(11): 1873-1883.
doi: 10.1007/s00259-018-4048-6 |
| [22] |
Fraum TJ, Ludwig DR, Kim EH, et al. Prostate cancer PET tracers: essentials for the urologist[J/OL]. Can J Urol, 2018, 25(4): 9371−9383[2023-02-07]. https://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=30125515. |
| [23] |
Karagiannis V, Wichmann V, Saarinen J, et al. Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT[J/OL]. Radiat Oncol, 2022, 17(1): 19[2023-02-07]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-022-01989-5. DOI: 10.1186/s13014-022-01989-5. |
| [24] |
Calais J, Kishan AU, Cao MS, et al.
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer[J]. J Nucl MedJ Nucl Med, 2018, 59(11): 1714-1721.
doi: 10.2967/jnumed.118.209387 |
| [25] |
Hoffmann MA, Wieler HJ, Baues C, et al.
The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer[J]. UrologyUrology, 2019, 130: 1-12.
doi: 10.1016/j.urology.2019.04.004 |
| [26] |
Mingels C, Bohn KP, Rominger A, et al.
Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(7): 2436-2444.
doi: 10.1007/s00259-022-05693-0 |
| [27] |
Beheshti M, Manafi-Farid R, Geinitz H, et al.
Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: a prospective study of 135 patients[J]. J Nucl MedJ Nucl Med, 2020, 61(10): 1484-1490.
doi: 10.2967/jnumed.119.238071 |
| [28] |
Ferrari M, Treglia G.
18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis[J]. Contrast Media Mol ImagingContrast Media Mol Imaging, 2021, : 3502389-.
doi: 10.1155/2021/3502389 |
| [29] |
Huo HS, Shen SR, He D, et al.
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies[J]. Prostate Cancer Prostatic DisProstate Cancer Prostatic Dis, 2023, 26(1): 16-24.
doi: 10.1038/s41391-022-00581-y |
| [30] |
Manafi-Farid R, Ranjbar S, Jamshidi Araghi Z, et al. Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends[J/OL]. Cancers (Basel), 2021, 13(21): 5360[2023-02-07]. https://www.mdpi.com/2072-6694/13/21/5360. DOI: 10.3390/cancers13215360. |
| [31] |
Zamboglou C, Carles M, Fechter T, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference[J/OL]. Theranostics, 2019, 9(9): 2595−2605[2023-02-07]. https://www.thno.org/v09p2595.htm. DOI: 10.7150/thno.32376. |
| [32] |
Papp L, Spielvogel CP, Grubmüller B, et al.
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(6): 1795-1805.
doi: 10.1007/s00259-020-05140-y |
| [33] |
Solari EL, Gafita A, Schachoff S, et al.
The added value of PSMA PET/MR radiomics for prostate cancer staging[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(2): 527-538.
doi: 10.1007/s00259-021-05430-z |
| [34] |
中华医学会泌尿外科学分会, 中国前列腺癌研究协作组.
前列腺穿刺中国专家共识(2022年版)[J]. 中华泌尿外科杂志中华泌尿外科杂志, 2022, 43(11): 801-806.
doi: 10.3760/cma.j.cn112330-20221111-00005 Chinese Prostate Cancer Consortium, Chinese Urological Association. Chinese expert consensus on prostate biopsy (2022 edition)[J]. Chin J UrolChin J Urol, 2022, 43(11): 801-806. doi: 10.3760/cma.j.cn112330-20221111-00005 |
| [35] |
Satapathy S, Singh H, Kumar R, et al.
Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis[J]. AJR Am J RoentgenolAJR Am J Roentgenol, 2021, 216(3): 599-607.
doi: 10.2214/AJR.20.23912 |
| [36] |
Zhang LL, Li WC, Xu Z, et al.
68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(2): 483-492.
doi: 10.1007/s00259-020-04863-2 |
| [37] |
Liu C, Liu TL, Zhang ZY, et al.
68Ga-PSMA PET/CT combined with PET/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results[J]. J Nucl MedJ Nucl Med, 2020, 61(9): 1314-1319.
doi: 10.2967/jnumed.119.235333 |
| [38] |
Qiu DX, Li J, Zhang JW, et al.
Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(8): 2821-2832.
doi: 10.1007/s00259-021-05636-1 |
| [39] |
Karl A, Konety B. Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences[J/OL]. F1000 Med Rep, 2009, 1: 2[2023-02-07]. https://connect.h1.co/prime/reports/pubmed/20948762. DOI: 10.3410/M1-2. |
| [40] |
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J MedN Engl J Med, 2021, 385(12): 1091-1103.
doi: 10.1056/NEJMoa2107322 |
| [41] |
Satapathy S, Mittal BR, Sood A, et al.
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(5): 1754-1764.
doi: 10.1007/s00259-021-05618-3 |
| [42] |
Hofman MS, Violet J, Hicks RJ, et al.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet OncolLancet Oncol, 2018, 19(6): 825-833.
doi: 10.1016/S1470-2045(18)30198-0 |